Is DELCATH SYSTEMS, INC. (DCTH) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.3% / 30% | 28.4% / 30% | 4.0% / 30% | 0.08% / 5% | ✓ HALAL |
| DJIM | 0.3% / 33% | 28.4% / 33% | 4.0% / 33% | 0.08% / 5% | ✓ HALAL |
| MSCI | 0.8% / 33% | 73.6% / 33% | 10.5% / 33% | 0.08% / 5% | ✗ NOT HALAL |
| S&P | 0.3% / 33% | 28.4% / 33% | 4.0% / 33% | 0.08% / 5% | ✓ HALAL |
| FTSE | 0.8% / 33% | 73.6% / 33% | 10.5% / 50% | 0.08% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 86.2% | |
| Operating Margin | -10.5% | |
| Net Margin | 3.2% | |
| Return on Equity (ROE) | 3.0% | |
| Return on Assets (ROA) | 0.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $23M |
| Free Cash Flow | $21M |
| Total Debt | $936,000 |
| Debt-to-Equity | 0.8 |
| Current Ratio | 10.9 |
| Total Assets | $124M |
Price & Trading
| Last Close | $9.13 |
| 50-Day MA | $9.60 |
| 200-Day MA | $10.55 |
| Avg Volume | 480K |
| Beta | 0.5 |
|
52-Week Range
$8.12
| |
About DELCATH SYSTEMS, INC. (DCTH)
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.
Purification Calculator
As a halal stock with 0.08% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is DELCATH SYSTEMS, INC. (DCTH) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), DELCATH SYSTEMS, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is DELCATH SYSTEMS, INC.'s debt ratio?
DELCATH SYSTEMS, INC.'s debt ratio is 0.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.8%.
Does DELCATH SYSTEMS, INC. require dividend purification?
Yes, DELCATH SYSTEMS, INC. has an impermissible income ratio of 0.08%, which means 0.08% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are DELCATH SYSTEMS, INC.'s key financial metrics?
DELCATH SYSTEMS, INC. has a market capitalization of $317M, trailing P/E ratio of 128.1, and revenue of $85M. The company maintains a gross margin of 86.2% and a net margin of 3.2%. Return on equity stands at 3.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.